“ZEVASKYN’s approval just a few weeks ago is a landmark achievement for recessive dystrophic epidermolysis bullosa patients and signifies Abeona’s transition to a commercial-stage cell and gene therapy company,” said Vish Seshadri, Chief Executive Officer of Abeona. “We are rapidly advancing the launch of ZEVASKYN and building positive momentum. Patients can now start their treatment journey with Lurie Children’s activated as our initial treatment center ready to identify patients and our scheduling system is operational. In addition, we are collecting patient registrations through our patient support program, Abeona Assist, and have entered into agreements with commercial payer groups ensuring broad access to ZEVASKYN.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona, Lurie Children’s opens first center for ZEVASKYN gene therapy
- Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives
- Abeona Therapeutics Sells Priority Review Voucher for $155M
- Abeona Therapeutics enters agreement to sell PRV for $155M
- ABEO Earnings this Week: How Will it Perform?